I have little knowledge of FOLFOX. I read it for the first time today in the poster. I’m happy you were able to find an effective treatment after a number of varied approaches.
Your personal anecdote speaks to the difficulties treating bile duct cancers. As @LHI 14 mentioned, any improvements to prognosis and treatments will be eagerly and positively received. I agree it is easy to point to a (preliminary) ORR of 8.3% and feel disappointed, but this seems to be low-hanging fruit for detractors.
- IMU intentionally targeted cholangiocarcinoma due to early positive signals in the MAST trial as well as a lower burden of existing treatments to surpass. This is a strategic move to expedite time to market. - CCA is difficult to treat & trial patients are very sick and heavily pre-treated. - This is preliminary data with more to come as the trial progresses. - Although this may not seem like knockout data it presents a significant improvement on existing treatments which may bode well for regulatory approval.
Wishing all holders and patients a nice weekend.
Shornbra
IMU Price at posting:
2.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)